CEA, TPA, CA 15-3 were assayed in 238 patients in follow-up for breast cancer after surgery. CA 15-3 showed the best sensitivity and specificity; the predictive value of a positive CA 15-3 test was three times higher than CEA and TPA. No association was found between marker positivity and the number of organs involved by metastases. CA 15-3 positivity was significantly associated with visceral rather than soft tissue recurrences; no significant similar association was observed for CEA and TPA. CA 15-3 serum levels were early predictors of relapse in four out of nine patients within a 6-12 month follow-up period.
KufeD.W., InghiramiG., AbeM.Differential reactivity of a novel monoclonal antibody (DF3) with human versus benign breast tumors. Hybridoma1984; 3: 223–32.
2.
SekineH., OhnoT., KufeD.W.Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol1985; 135: 3610–5.
3.
ScheflerW.C.Statistics for health professionals.Addison Wesley Publishing Company Inc, 1984.
4.
TormeyD., WaalkesT., SnyderJ.Biological markers in breast carcinoma. III. Clinical correlations with carcinoembryonic antigen. Cancer1977; 39: 2397–404.
5.
TormeyD., WaalkesT.Clinical correlation between CEA and breast cancer. Cancer1978; 42: 1507–11.
6.
LoprinziC., TormeyD., RasmussenP.Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. J Clin Oncol1986; 4: 46–56.
7.
BjorklundB.On the nature and clinical use of tissue polypeptide antigen (TPA). Tumor Diagnostik1980; 1: 8–20.
8.
LuthgensM., SchlegelG.CEA + TPA in clinical tumor diagnosis with special reference to breast cancer. Tumor Diagnostik1980; 1: 63–77.
9.
BezwodaW., DermanD., BothwellT.Significance of serum concentrations of CEA, ferritin, and calcitonin in breast cancer. Cancer1981; 48: 1623–8.
10.
SchapiraD., SchapiraM.Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res Treat1983; 3: 221–4.
11.
ThompsonR.J., RuberyE., JonesH.M.Radioimmunoassay of serum creatine kinase BB as a tumor marker in breast cancer. Lancet1980; 2: 673–5.
12.
StewartJ., RubensR., MillisR.Postoperative serum sialyltransferase levels and prognosis in breast cancer. Breast Cancer Res Treat1983; 3: 225–30.
13.
HayesD.F., SekineH., OhnoT.Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest1985; 75: 1671–7.
14.
GionM., MioneR., DittadiR.Carcinoembryonic antigen, ferritin, tissue polypeptide antigen and CA 15-3 in breast cancer: relationship between carcinoma and normal breast tissue. Int J Biol Markers1986; 1: 33–8.
15.
HayesD.F., ZurawskiV.R., KufeD.W.Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol1986; 4: 1542–50.
16.
ColomerR., SoleL.A., NavarroM., EncaboG., RuibalA., SalvadorL.CA 15-3: early results of a new breast cancer marker. Anticancer Res1986; 6: 683–4.
17.
NamerM., KrebsB.P., HeryM., AubanelD., KhaterR., FrenayM.CEA versus CA 15-3 as markers for metastasized breast cancer. Proc Ann Meet Am Soc Clin Oncol1986; 5: 24.
